First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative
Blood Adv
.
2022 Nov 8;6(21):5711-5715.
doi: 10.1182/bloodadvances.2022007977.
Authors
Hiroshi Azuma
1
,
Toraji Amano
2
,
Naoya Kamiyama
3
,
Naofumi Takehara
3
,
Maki Jingu
2
,
Harumi Takagi
2
,
Osamu Sugita
2
,
Naoko Kobayashi
4
,
Tomoko Kure
4
,
Taro Shimizu
5
,
Tatsuhiro Ishida
5
,
Masanori Matsumoto
6
7
,
Hiromi Sakai
4
Affiliations
1
Department of Pediatrics, Asahikawa Medical University, Asahikawa, Japan.
2
Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.
3
Clinical Research Support Center, Asahikawa Medical University, Asahikawa, Japan.
4
Department of Chemistry, Nara Medical University, Kashihara, Japan.
5
Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima, Japan.
6
Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan.
7
Cell Processing Center, Nara Medical University Hospital, Kashihara, Japan.
PMID:
35939788
PMCID:
PMC9618780
DOI:
10.1182/bloodadvances.2022007977
No abstract available
Publication types
Clinical Trial, Phase I
Research Support, Non-U.S. Gov't
MeSH terms
Blood Substitutes* / adverse effects
Blood Transfusion
Erythrocytes
Hemoglobins
Humans
Substances
Blood Substitutes
Hemoglobins